Tessa, St. Jude partner to develop cellular immunotherapies for pediatric brain cancers

Tessa Therapeutics Pte. Ltd. (Singapore) and St. Jude Children's Research Hospital partnered to develop CAR-expressing virus-specific T cells to treat pediatric brain cancers using Tessa's virus-specific T cell technology.

Using Tessa's technology, a patient's cytotoxic T cells are extracted and stimulated to target tumor cells with viral antigens, and then are reintroduced into the patient. Tessa's lead candidate Epstein-Barr Virus-Specific T Cells (EBVST), which comprises EBV-specific cytotoxic T lymphocytes, is in a Phase III trial to treat advanced nasopharyngeal carcinoma...